To obtain protein crystals, researchers must search for conditions in multidimensional chemical space. Empirically, thousands of crystallization experiments are carried out to screen various precipitants at multiple concentrations. Microfluidics can manipulate fluids on a nanoliter scale, and it affects crystallization twofold. First, it miniaturizes the experiments that can currently be done on a larger scale and enables crystallization of proteins that are available only in small amounts. Second, it offers unique experimental approaches that are difficult or impossible to implement on a larger scale. Ongoing development of microfluidic techniques and their integration with protein production, characterization, and in situ diffraction promises to accelerate the progress of structural biology. 
INTRODUCTION
This review discusses the use of microfluidics in protein crystallization for structural determination using single-crystal X-ray diffraction. Elucidation of three-dimensional protein structures via X-ray crystallography has been the basis for understanding biophysical and biochemical mechanisms (17, 22) . However, identifying the correct conditions for protein crystallization is complex because a large chemical space must be explored (3, 6, 25, 57) . Microfluidics is a technology that manipulates small (nanoliter to femtoliter) amounts of fluids (2, 21, 24, 35, 39, 52, 69, 72, 78, [81] [82] [83] [84] [85] 87) , and it affects the field of protein crystallization in two ways. First, it allows miniaturization of experiments that are already possible on a larger scale. Because samples of many proteins are rare and reagents can be expensive, it is advantageous to perform these trials with small volumes. Second, microfluidics provides unique experimental approaches that are difficult or impossible to implement on a larger scale, such as precise control of diffusion of molecules and nucleation of crystals.
In the first part of this review, we discuss protein crystallization in terms of a simple protein-precipitant phase diagram. We discuss four traditional methods for protein crystallization: microbatch, vapor diffusion, dialysis, and free interface diffusion (FID). We then turn our attention to microfluidic approaches, first looking at established microfluidic approaches to implement microbatch, vapor diffusion, and FID methods, and then looking at emerging microfluidic approaches. We then consider the membrane protein crystallization using microfluidic methods and discuss the diffraction of crystals obtained from microfluidic experiments. Finally, we briefly explore the future of protein crystallization and the use of microfluidics to further this field.
PROTEIN CRYSTALLIZATION: PHASE DIAGRAM AND TRADITIONAL METHODS
Obtaining protein crystals remains an obstacle to solving their structures (6, 7, 19, 29, 74, 88) , thus hindering investigators from elucidating their functions at the molecular level (17, 22, 28, 41-43, 53, 61) . Because protein crystallization is generally an empirical process, obtaining high-quality crystals for X-ray diffraction requires exploration of multidimensional chemical space, an ambitious undertaking that can involve screening multiple precipitants of various concentrations in hundreds or thousands of individual crystallization trials (18, 40, 54, 55, 68, 77) . This exploration of chemical space can be represented by using a phase diagram. In the simplest version, a phase diagram graphically shows whether a protein is soluble or not under various conditions.
Here we illustrate the concept of the phase diagram by using a two-dimensional version (Figure 1) . In this diagram (5), conditions for crystallization are described by two parameters: protein concentration and precipitant concentration. In more realistic situations, many other factors, such as protein purity, pH, temperature, ionic strength, types of buffer, additives, and precipitants, must be considered, and the phase diagram may have dozens of dimensions and discontinuous regions (3, 7, 57). The phase diagram plots the solubility curve of the protein (see Figure 1 for more details).
Within the zone of supersaturation there are three other zones: nucleation, precipitation, and metastable (Figure 1 ). In the nucleation zone, the concentration of protein is high enough for nuclei to form spontaneously and to reach a critical size to support subsequent crystal growth. In the precipitation zone, the concentration of the protein is too high and nucleation and growth occur too rapidly, resulting in disordered structures such as aggregates and precipitates. In the metastable zone, the concentration of the protein is too low and no new nuclei will form, although existing crystals can continue to grow. Because these zones are related to kinetic phenomena, the boundaries between them are not well defined. For example, under the same conditions, incubation lasting a few seconds may lead to nucleation, whereas hours-long incubation may lead to precipitation. Chemical space in crystallization experiments is multidimensional, and several zones may correspond to nucleation and growth of different crystal forms and polymorphs. For membrane proteins, the search for conditions for crystallization is more complicated. Detergents, lipids, or both may be required to solubilize and stabilize membrane proteins of interest; their addition inevitably requires a revised phase diagram involving the detergents or lipids (14, 56, 64, 74, 89) . Nevertheless, the zones can serve as guide when searching for the appropriate conditions to crystallize a particular protein.
Microbatch methods (9, 10) are based on finding a starting point on the phase diagram where crystallization occurs. The starting point must be in the nucleation zone (Figure 1) . Supersaturation occurs upon mixing the protein and the crystallizing agents in a small droplet, and the conditions in the droplet change only as the protein comes out of solution. If the conditions are correct, nuclei will form and crystals will begin to grow on the nuclei. As crystals grow, the concentration of protein begins to fall rapidly. Once the line reaches the metastable zone, no new nuclei will form, but the ordered growth of crystals will continue on the existing nuclei until the line intersects the solubility curve.
Vapor diffusion (34, 44, 58), dialysis (67, 90) , and FID methods (71) are based on finding a path through the phase diagram that leads to crystallization. In vapor diffusion, the crystallization trial starts at a point in the undersaturation zone. A droplet containing a solution of protein and precipitant is allowed to equilibrate with a larger reservoir containing a solution of the precipitant, sometimes referred to as mother liquor, at a higher concentration. As water evaporates from the droplet, protein and precipitant concentrations in the droplet increase (Figure 1) . Once the path reaches the nucleation zone, the protein in the droplet starts to nucleate. This nucleation is followed by crystal growth and a drop in the protein concentration, similar to the growth described for microbatch.
In dialysis, pure solutions of protein and precipitant are separated by a membrane that is impermeable to protein but that allows passage of the precipitant. The crystallization trial, on the side of the membrane containing the protein, starts at a low precipitant concentration. The precipitant diffuses across the dialysis membrane into the protein solution, causing an increase in precipitant concentration. Because the protein can not diffuse across the membrane, its concentration stays the same (Figure 1) . Once the path reaches the nucleation zone, the protein starts to nucleate and then crystals start to grow, similar to the growth described for microbatch.
In FID, protein and precipitant gradually diffuse under the influence of a concentration gradient. Initially, pure solutions of protein and precipitant are connected by an interface. At this interface, the protein begins to diffuse into the precipitant solution, and the precipitant begins to diffuse into the protein solution. On the protein side, the amount of protein decreases as it diffuses into the precipitant solution and the amount of precipitant increases as it diffuses into the protein solution (Figure 1) . When the path enters the nucleation zone, nuclei begin to form and support the following growth, similar to that described for microbatch. In counterdiffusion (30, 63), the precipitant is placed on one side of an elongated protein sample, usually in a capillary. Because counterdiffusion uses principles similar to FID to explore the crystallization path, we discuss it as an FID approach.
Any technology that explores the chemical space to identify conditions for crystallization should (a) be capable of carrying out many experiments simultaneously to provide sufficiently dense coverage of the multidimensional chemical space, (b) use small quantities of samples to carry out these experiments, (c) precisely control mixing, interfaces, and time of contact between solutions, and (d ) enable evaluation of a crystal's quality by X-ray diffraction. Microfluidic approaches satisfy these criteria and are thus attractive for crystallizing proteins.
MICROFLUIDIC APPROACHES
We describe three microfluidic approaches used to explore the chemical space to identify conditions for protein crystallization: (a) valve-based systems (37) (Figure 2a) , (b) droplet-based systems (94) (Figure 2b) , and (c) systems based on SlipChip and related well-based approaches (23, 98) (Figure 2c ). All these systems define nanoliter volumes in which crystallization takes place, but they define these volumes differently. In valve-based systems (37) (Figure 2a) , different aqueous reagents are loaded into different chambers. A protein sample and a precipitant can be mixed by opening the valve that connects the chambers to form crystallization trials. Loading different precipitants into chambers and mixing precipitants with protein are all initiated by separately operating different pneumatic valves in their open or closed states. In droplet-based systems (Figure 2b) , crystallization takes place inside aqueous volumes surrounded by an immiscible carrier fluid. To optimize crystallization conditions, hundreds of droplets, each containing different crystallization conditions, can be generated in a single experiment by systematically changing the flow rates of the streams of aqueous reagent, protein, buffer, and precipitants, and by flowing these streams into fluorinated carrier fluid. In SlipChip (23) (Figure 2c) , the solutions are loaded into wells in two plates that can move relative to one another. This motion of the plates brings protein and precipitant solutions into contact, initiating crystallization. The volumes of the precipitant solution and protein solution are defined by the volumes of the corresponding wells, without a need for metering each volume. Nanoliter wells are filled precisely with a protein solution as the protein solution is introduced through a series of wells and ducts. Movement of the plates disconnects all the wells from the ducts, isolates the wells containing the protein, and then brings them in contact with the wells containing preloaded precipitants, thus initiating crystallization.
PROTEIN CRYSTALLIZATION IN MICROFLUIDICS: IMPLEMENTING ESTABLISHED METHODS
In this section, we discuss how the traditional approaches to protein crystallizationmicrobatch, vapor diffusion, and FID-have been implemented on a ∼10-nL scale using microfluidics.
Microfluidic Approaches to Implement Microbatch Methods
To implement the microbatch method in the droplet-based microfluidic system (92), the protein, buffer, and precipitant solutions flow in through different aqueous channels, meet at the junction, and form a droplet. A fluorinated carrier fluid transports the droplet (Figure 3) . solutions and does not have chemical exchange with the droplets. As a result, all the droplets are separated and no evaporation or loss of chemicals occurs. Thus, each droplet is an individual microbatch crystallization trial. In this system, concentration gradients can be created by varying independently the flow rates of protein stream, buffer stream, and precipitant stream (94) (95) (96) . The protein can be merged with a stream containing an array of droplets, each of which contains a different precipitant; as a result, a sparse matrix screening can be performed (12, 93) . Furthermore, those two experiments can be combined into a hybrid method, in which different precipitants are screened and each precipitant is tested at multiple concentrations in one experiment. In such an experiment, one researcher can set up approximately 1300 crystallization trials using 10 μL protein within 20 min (50).
To implement the microbatch method in a well-based system (98), two glass plates containing wells are brought into close contact. Each well is individually user-loaded by a degassing method under a sacrificial polydimethylsiloxane (PDMS) slab; one plate is loaded with various precipitants, the other plate is loaded with the protein sample. The loaded plates are then aligned on top of each other to bring wells containing precipitants and wells containing protein samples into contact to form individual crystallization trials. The plates are stored under paraffin oil to prevent evaporation.
The SlipChip is another well-based system that uses two plates containing wells (23, 48). There are two ways to implement the microbatch method in the SlipChip: preloaded and user-loaded. In the preloaded SlipChip (Figure 2c ) (23), the bottom plate contains an array of wells preloaded with different precipitants. These wells are covered by the top plate, which acts as a lid for the precipitant-containing wells. The chip also has a fluidic path, composed of an array of disconnected ducts in the bottom plate and an array of wells in the top plate (complementary to the array of wells in the bottom plate), that is connected only when the top and bottom plates are aligned in a specific configuration. A protein sample can be introduced into the fluidic path, filling both wells and ducts. Then, the top plate is slipped, or moved, relative to the bottom plate to bring proteinand precipitant-containing wells in contact to form crystallization trials. Each corresponding set of wells forms a single crystallization trial. In the user-loaded SlipChip (Figure 4 ) (48), no precipitants are preloaded. The user-loaded SlipChip contains different fluidic paths for different precipitants and a separate fluidic path for the protein sample. By simply pipetting an aliquot of solution into a fluidic path, all the wells in that path can be filled. The respective wells of precipitants and the protein sample can be designed to have different volumes while the combined volume of each trial remains the same. As a result, different precipitants and different protein-precipitant ratios for each precipitant can be screened at the same time in one SlipChip. Less than 4 μL of a protein sample was used to screen 16 precipitants and 11 mixing ratios for each precipitant, totaling 176 crystallization trials on a single SlipChip.
Microfluidic Approaches to Implement Vapor Diffusion Methods
Three microfluidic methods have been developed to perform vapor diffusion. The first method, which is both valve and droplet based, relies on a formulator module to create mixtures of precipitants and a protein sample and on a two-phase injector to create nanoliter volume droplets encapsulated in an immiscible carrier fluid (46). Each droplet comprises an individual crystallization trial, and an osmotic bath dehydrates the droplets to mimic the vapor diffusion process (Figure 5a ). The second method, which is droplet based, generates alternating droplets of crystallization trials (trial droplet) and solutions with high salt concentration (salt droplet) (Figure 5b) . A fluorinated carrier fluid physically separates the droplets. Because the carrier fluid is water permeable, the salt droplet with high salt concentration dehydrates the adjacent trial droplets. This dehydration stops when the osmotic pressure in the trial and salt droplets becomes the same (97) . The third method is also based on droplets (76) and is described in more detail below.
Microfluidic Approaches to Implement FID Methods
FID methods rely on diffusion of precipitant and protein. The path through the phase diagram for FID is different from that for vapor diffusion, (71) , which resulted in a higher success rate for crystallization trials (37). However, setting up experiments for crystallization using FID requires careful manipulation of fluids and has only rarely been performed since its development in 1972. A microfluidics system using valves was developed to meter nanoliter volumes of fluids, which allowed FID experiments to be performed in a robust way (37). By using a valve-based formulator, phase knowledge can be obtained (38) (Figure 6a-c) and this knowledge enables rational screens using on-chip FID (1) (Figure 6d-f ). Moreover, due to the flexibility in the design of the chip, different diffusion times between the protein and precipitant are obtained by altering the length of connecting channels through which diffusion occurs (Figure 6g) . Another microfluidic system was recently developed to perform FID experiments based on SlipChip (23). In this system, all protein and precipitant solutions were loaded by pipetting, and the connection of protein to precipitant was initiated by slipping the connecting channels to bridge the protein wells and the precipitant wells, with FID taking place through the bridge (47). For this process, no specialized equipment is necessary. This SlipChip allows one protein sample to be screened against multiple precipitants, as well as multiple diffusion times to be screened for each precipitant (Figure 7) . (20, 62) . A protein solution is fully loaded into these long channels, and different precipitants are placed on top of the outlets of the channels. Diffusion occurs through the outlets and a gradient of precipitant concentrations can be formed along those channels. These and related traditional methods [such as gel acupuncture (31)] are attractive because of their simplicity, although they typically require larger volumes of protein than other methods described in this review.
PROTEIN CRYSTALLIZATION IN MICROFLUIDICS: EMERGING METHODS
Despite the success of the traditional approaches in crystallizing proteins described above, many proteins are recalcitrant to crystallization. The optimal conditions for crystallization may be difficult to determine for many reasons. For example, the nucleation zone and the metastable zone may lie in different parts of the phase diagram, in some cases even discontinuous parts of the phase diagram. Traditional approaches for bridging this gap include inducing nucleation by adding minerals or synthetically designed nucleants (8, 59 ), altering concentrations of protein and reagents by using approaches such as FID, varying temperature, and seeding. Although these traditional approaches
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have had some measure of success, microfluidic methods can provide additional capabilities for precise control of the time and position of each crystallization trial in the chemical space. Microfluidic approaches, such as precise control of mixing (11) and nucleation (32, 33, 45, 70, 76), may be difficult or impossible to implement on larger scales.
Proteins may be difficult to crystallize if the nucleation zone and the metastable zone on the phase diagram have different optimal conditions. Although FID can be used in some of these cases, microfluidic technologies can also bridge this gap by decoupling the nucleation and metastable regions of the phase diagram. It must be established whether the path from the nucleation zone into the
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Nucleate Grow metastable zone is continuous or discontinuous. If the path is continuous, microfluidics can be used to control evaporation and rehydration to decouple nucleation and growth, which can be accomplished by using the Phase Chip (76) (Figure 8 ). This device is constructed from two PDMS layers that are sealed together. In the upper, thick (5-mm) layer there are flow channels and storage wells. In the lower, thin (40-μm) layer there is a reservoir sealed by a 15-μm-thick PDMS membrane. Water vapor flows primarily between the drop and the reservoir, but it can also flow through the thick PMDS layer. Initially, there is protein solution in the well and a reservoir below filled with 6 M NaCl. Then, the water flows out of the drop, owing to the osmotic pressure. This dehydration leads to the formation of crystal nuclei. Next, the reservoir is filled with a lower concentration of NaCl, which changes the osmotic pressure. The water flows back into the drop, and the path moves from the nucleation zone to the metastable zone on the phase diagram. At this point, the existing nuclei continue to grow into crystals, but no new nuclei form. If the path from the nucleation zone into the metastable zone is discontinuous, microfluidic approaches offer control of nucleation time with subsecond precision in nanoliter volumes. To take advantage of these features, Gerdts et al. (32, 33) have developed a droplet-based microfluidic system to separate and independently control the nucleation and growth stages of protein crystallization to allow the growth of singleprotein crystals (Figure 9 ). This approach enables a jump from the nucleation region to the metastable region of the phase diagram. Microfluidic approaches also address the problems that arise when there is a narrow window of conditions in which nucleation occurs. Microfluidic systems may overcome this problem by controlling interfaces to promote nucleation and extend this region of the phase diagram. Roach et al. (70) modified a previously developed fluorous surfactant with an oligoethylene glycol head group, RfOEG, to design a new fluorinated amphiphile, RfNTA, which introduces specific adsorption of His-tag proteins at the interface to create laterally mobile self-assembled monolayers. The formation of self-assembled monolayers increased the range of successful conditions, the success rate at a given condition, the rate of nucleation, and the quality of the crystals formed when applied to membrane protein crystallization (45). Microfluidic systems, with their high surface-to-volume ratios, are especially sensitive to interfacial effects.
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PROTEIN CRYSTALLIZATION IN MICROFLUIDICS: MEMBRANE PROTEINS
There are additional considerations and methods for membrane protein crystallization because of the increased complexity of the process. First, using a lipidic mesophase, such as the lipidic cubic phase (LCP), is an attractive route to crystallize membrane proteins because the lipidic mesophase provides an environment similar to the natural environment of membrane proteins (4). Current developments in LCPbased microscale protein crystallization include robotic systems that allow for accurate handling of small amounts of LCP material (13) . LCP is highly viscous and is challenging to handle inside microfluidic devices. Nevertheless, Perry et al. (65) developed a microfluidic system that used pneumatic valves to form a LCP on-chip at volumes below 20 nL to crystallize membrane proteins (Figure 10) . Droplet-based microfluidic systems are suitable for handling viscous solutions-even suspensions of solids (75) and clotted blood (80)-because of the lubricating layer of carrier fluid that separates the sample inside the droplet from the channel wall. Li et al. (49) developed a droplet-based microfluidic system to dispense nanoliter-volume droplets of LCP material and subsequently merge the LCP droplets with aqueous droplets to form crystallization trials (Figure 11 ).
Second, a wide variety of detergents are commonly used to stabilize membrane proteins, but these detergents can interfere with 51) developed an approach that used cyclodextrin-based hostguest chemistry in a microfluidic device to capture and sequester detergent monomers to modulate membrane protein crystallization. This approach was used to simplify the process of protein concentration by removing free detergent micelles and to affect the packing of protein-detergent complexes by removing loosely bound detergent. Using hostguest chemistry, the detergent capture approach could be expanded to include timecontrolled removal of loosely bound detergent or more controlled thermodynamics suitable for selective binding with different detergents. Incorporating various detergent exchange protocols into microfluidic screens is an attractive opportunity, especially alongside the development of designer detergents (60, 91 
CONCLUSION AND FUTURE DIRECTIONS
Membrane proteins control many signaling pathways and are the targets of more than 50% of pharmaceutical drugs. If we understand the structures of the complexes formed between membrane proteins and their biological partners, we will enhance our knowledge of many basic cellular functions. Although many new structures of membrane proteins have been discovered, there remains a huge gap between the number of solved structures for membrane proteins and the number of solved structures for soluble proteins (86) . Implementation of current microfluidic technologies has been focused on soluble proteins, but to address this gap, these technologies must now be focused on membrane proteins and their complexes. Some of the microfluidic technologies discussed in this review may be immediately applicable to crystallizing membrane proteins, and some may require modifications before they can be applied to this problem. Although large surfaceto-volume ratios of microfluidic devices could be useful (45), they also present a potential problem, especially for solutions used in crystallization of membrane proteins containing detergents and other amphiphiles. Unless surface properties are controlled, the surfaces of microfluidic devices would likely cause losses of these molecules and thus affect crystallization.
Although screening of crystallization conditions and the actual crystallization experiments to obtain crystals suitable for X-ray diffraction can be performed in small volumes, currently these experiments begin by producing a large volume of protein samples. In addition, the thousands of trials generated by microfluidic experiments require efficient imaging systems to monitor the results and reliable database systems to manage the results (66) . By developing methods (15) to quickly prescreen crystallization conditions in small volumes so that only useful reagents are screened, fewer but more meaningful data points must be collected and managed. To affect how these problems are addressed requires the development of technologies for the production, purification, and biophysical characterization of proteins on small scales.
Once crystals are obtained from the microfluidic experiments, they need to be characterized by X-ray diffraction. The minimum trial volume that produces crystals large enough for X-ray diffraction is ∼10 nL (37, 50), although advances in synchrotron facilities may enable analysis of smaller crystals (16, 73) . Extraction of crystals from microfluidic devices is well established (37, 50). An exciting possibility is provided by X-ray diffraction of crystals in situ, inside the device, with many microfluidic methods compatible with both in situ diffraction to evaluate crystal quality (37, 50) and in situ diffraction to determine crystal structure (20, 36, 62, 97) . Diffraction in situ is preferred because it eliminates the potential for researchers to damage the crystal during postcrystallization manipulation. Diffraction in situ is especially important for membrane proteins, because membrane protein crystals have a higher solvent content and thus are more prone to damage during postcrystallization manipulation. Microfluidic systems and future advances described in this review, combined with ongoing dissemination of technologies (26, 27), are likely to accelerate further the progress of structural biology.
SUMMARY POINTS
1. To obtain protein crystals, a large chemical space must be searched to identify optimal conditions for crystallization. This requires thousands of crystallization experiments. 
